Sunday, June 5, 2022

Promising rectal cancer study

A scientist comments on the evolving treatment of rectal cancer in light of findings from a study that found the immunotherapy drug dostarlimab was especially effective in a phase II clinical trial of a dozen patients with a subtype of rectal cancer.

from Top Health News -- ScienceDaily https://ift.tt/wPA07Vg
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Study finds untreated sleep apnea doubles Parkinson’s risk

A massive veteran study found a strong connection between untreated sleep apnea and a higher chance of Parkinson’s. CPAP users had much lowe...